We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
Read MoreHide Full Article
Key Takeaways
IONS shares rose 2.5% after the European Commission approved Dawnzera to prevent recurrent HAE attacks.
Ionis partnered with Otsuka ex-U.S., & is eligible for a $15M milestone payment with approval in the EU.
Dawnzera cut mean monthly HAE attacks by 94% at one year in the OASISplus study.
Ionis (IONS - Free Report) and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
The approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion in November recommending the approval of Dawnzera. The FDA had approved Dawnzera in the United States in August last year for prophylaxis to prevent attacks of HAE, a rare and potentially life-threatening genetic condition.
Ionis has a partnership with Otsuka Pharmaceutical to market Dawnzera across ex-U.S. territories. Ionis is entitled to receive $15 million as a milestone payment from Otsuka following Dawnzera’s approval in the European Union. Ionis is also entitled to earn tiered royalties of up to 30% on net product sales.
Ionis shares rose around 2.5% on Wednesday in response to the EU approval news.
Over the past year, IONS’ shares have surged 130.5% against the industry’s 3.3% fall.
Image Source: Zacks Investment Research
EU Nod Based on IONS’ Phase III OASIS-HAE & OASISplus Studies
Dawnzera’s EU approval was supported by robust efficacy and safety data from the phase III OASIS-HAE and OASISplus studies. Data from the studies showed that treatment with Dawnzera led to a significant reduction in the mean monthly rate of HAE attacks. The OASISplus open-label extension study showed a 94% overall reduction in mean monthly attack rate at one year.
Hereditary angioedema is a rare inherited disorder that causes repeated attacks of severe swelling in different parts of the body, including the hands, feet, face, stomach, genitals, and throat. It affects approximately one in 50,000 people globally.
Dawnzera is an RNA-targeted preventive therapy designed to reduce the production of plasma prekallikrein involved in triggering HAE attacks. It is administered by subcutaneous injections and offers long dosing intervals of four to eight weeks. Dawnzera is the first and only RNA-targeted therapy for the treatment of HAE worldwide.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 4% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 61.8% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 58.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average earnings surprise being 20.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
Key Takeaways
Ionis (IONS - Free Report) and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
The approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion in November recommending the approval of Dawnzera. The FDA had approved Dawnzera in the United States in August last year for prophylaxis to prevent attacks of HAE, a rare and potentially life-threatening genetic condition.
Ionis has a partnership with Otsuka Pharmaceutical to market Dawnzera across ex-U.S. territories. Ionis is entitled to receive $15 million as a milestone payment from Otsuka following Dawnzera’s approval in the European Union. Ionis is also entitled to earn tiered royalties of up to 30% on net product sales.
Ionis shares rose around 2.5% on Wednesday in response to the EU approval news.
Over the past year, IONS’ shares have surged 130.5% against the industry’s 3.3% fall.
Image Source: Zacks Investment Research
EU Nod Based on IONS’ Phase III OASIS-HAE & OASISplus Studies
Dawnzera’s EU approval was supported by robust efficacy and safety data from the phase III OASIS-HAE and OASISplus studies. Data from the studies showed that treatment with Dawnzera led to a significant reduction in the mean monthly rate of HAE attacks. The OASISplus open-label extension study showed a 94% overall reduction in mean monthly attack rate at one year.
Hereditary angioedema is a rare inherited disorder that causes repeated attacks of severe swelling in different parts of the body, including the hands, feet, face, stomach, genitals, and throat. It affects approximately one in 50,000 people globally.
Dawnzera is an RNA-targeted preventive therapy designed to reduce the production of plasma prekallikrein involved in triggering HAE attacks. It is administered by subcutaneous injections and offers long dosing intervals of four to eight weeks. Dawnzera is the first and only RNA-targeted therapy for the treatment of HAE worldwide.
Ionis’ Zacks Rank & Stocks to Consider
IONS currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are MannKind (MNKD - Free Report) , Keros Therapeutics (KROS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 4% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 61.8% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 58.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average earnings surprise being 20.21%.